Bone marrow-mesenchymal stromal cells (BM-MSCs) have immunosuppressive properties and have been used in cell therapies as immune regulators for the treatment of graft-versus-host disease. We have previously characterized several biological properties of MSCs from placenta (PL) and umbilical cord blood (UCB), and compared them to those of BM—the gold standard. In the present study, we have compared MSCs from BM, UCB, and PL in terms of their immunosuppressive properties against lymphoid cell populations enriched for CD3+ T cells. Our results confirm the immunosuppressive potential of BM-MSCs, and demonstrate that MSCs from UCB and, to a lesser extent PL, also have immunosuppressive potential. In contrast to PL-MSCs, BM-MSCs and UCB-MSCs significantly inhibited the proliferation of both CD4+ and CD8+ activated T cells in a cell–cell contact-dependent manner. Such a reduced proliferation in cell cocultures correlated with upregulation of programmed death ligand 1 on MSCs and cytotoxic T lymphocyte-associated Ag-4 (CTLA-4) on T cells, and increased production of interferon-γ, interleukin-10, and prostaglandin E2. Importantly, and in contrast to PL-MSCs, both BM-MSCs and UCB-MSCs favored the generation of T-cell subsets displaying a regulatory phenotype CD4+CD25+CTLA-4+. Our results indicate that, besides BM-MSCs, UCB-MSCs might be a potent and reliable candidate for future therapeutic applications.
Get full access to this article
View all access options for this article.
References
1.
MeiselR, ZibertA, LaryeaM, GobelU, DaubenerW and DillooD. (2004). Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenasemediated tryptophan degradation. Blood, 103:4619–4621.
2.
AggarwalS and PittengerMF. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 105:1815–1822.
3.
JiangXX, ZhangY, LiuB, ZhangSX, WuY, YuXD and MaoN. (2005). Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood, 105:4120–4126.
4.
KramperaM, CosmiL, AngeliR, PasiniA, LiottaF, AndreiniA, SantarlasciV, MazzinghiB, PizzoloG, et al. (2006). Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells, 24:386–398.
5.
RyanJM, BarryF, MurphyJM and MahonBP. (2007). Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol, 149:353–363.
6.
MaccarioR, PodestàM, MorettaA, CometaA, ComoliP, MontagnaD, DaudtL, IbaticiA, PiaggioG, et al. (2005). Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica, 90:516–525.
7.
PrevostoC, ZancolliM, CanevaliP, ZocchiMR and PoggiA. (2007). Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica, 92:881–888.
8.
SelmaniZ, NajiA, ZidiI, FavierB, GaiffeE, ObertL, BorgC, SaasP, TiberghienP, et al. (2008). Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+ CD25highFOXP3+ regulatory T cells. Stem Cells, 26:212–222.
9.
EnglishK, RyanJM, TobinL, MurphyMJ, BarryFP and MahonBP. (2009). Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+ CD25(High) forkhead box P3+regulatory T cells. Clin Exp Immunol, 156:149–160.
10.
Le BlancK, RasmussonI, GotherstromC, SeidelC, SundbergB, SundinM, RosendahlK, TammikC and RingdenO. (2004). Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol, 60:307–315.
11.
RasmussonI, RingdenO, SundbergB and Le BlancK. (2005). Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res, 305:33–41.
12.
RamasamyR, TongCK, SeowHF, VidyadaranS and DazziF. (2008). The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function. Cell Immunol, 251:131–136.
13.
NajarM, RaicevicG, BoufkerHI, FayyadKH, DeBC, MeulemanN, BronD, ToungouzM and LagneauxL. (2010). Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: combined comparison of adipose tissue, Wharton's jelly and bone marrow sources. Cell Immunol, 264:171–179.
14.
KronsteinerB, WolbankS, PeterbauerA, HacklC, RedlH, van GriensvenM and GabrielC. (2011). Human mesenchymal stem cells from adipose tissue and amnion influence T-cells depending on stimulation method and presence of other immune cells. Stem Cells Dev, 20:2115–2026.
15.
KuzminaLA, PetinatiNA, ParovichnikovaEN, LubimovaLS, GribanovaEO, GaponovaTV, ShipounovaIN, ZhironkinaOA, BigildeevAE, et al. (2012). Multipotent mesenchymal stromal cells for the prophylaxis of acute graft-versus-host disease—a phase II study. Stem Cells Int, 2012:968213
16.
PhilippeB, LucS, ValériePB, JérômeR, AlessandraBR and LouisC. (2010). Culture and use of mesenchymal stromal cells in phase I and II clinical trials. Stem Cells Int, 2010:503593
17.
CaplanAI. (2009). Why are MSCs therapeutic?. New data: new insight. J Pathol, 217:318–324.
18.
MontesinosJJ, Flores-FigueroaE, Castillo-MedinaS, Flores-GuzmánP, Hernández-EstévezE, Fajardo-OrduñaG, OrozcoS and MayaniH. (2009). Human mesenchymal stromal cells from adult and neonatal sources: comparative analysis of their morphology, immunophenotype, differentiation patterns and neural protein expression. Cytotherapy, 11:163–176.
19.
AugelloA, TassoR, NegriniSM, AmateisA, IndiveriF, CanceddaR and PennesiG. (2005). Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol, 35:1482–1490.
20.
ShengH, WangY, JinY, ZhangQ, ZhangY, WangL, ShenB, YinS, LiuW, CuiL and LiN. (2008). A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Res, 18:846–857.
21.
GiulianiM, FleuryM, VernochetA, KetroussiF, ClayD, AzzaroneB, LatailladeJJ and DurrbachA. (2011). Long-lasting inhibitory effects of fetal liver mesenchymal stem cells on T-lymphocyte proliferation. PLoS One, 6:e19988
22.
Di NicolaM, Carlo-StellaC, MagniM, MilanesiM, LongoniPD, MatteucciP, GrisantiS and GianniAM. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood, 99:3838–3843.
23.
XuG, ZhangL, RenG, YuanZ, ZhangY, ZhaoRC and ShiY. (2007). Immunosuppressive properties of cloned bone marrow mesenchymal stem cells. Cell Res, 17:240–248.
24.
GrohME, MaitraB, SzekelyE and KocON. (2005). Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol, 33:928–934.
25.
Di IanniM, Del PapaB, De IoanniM, MorettiL, BonifacioE, CecchiniD, SportolettiP, FalzettiF and TabilioA. (2008). Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol, 36:309–318.
26.
GhannamS, PeneJ, Torcy-MoquetG, JorgensenC and YsselH. (2010). Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol, 185:302–312.
27.
MougiakakosD, JitschinR, JohanssonCC, OkitaR, KiesslingR and Le BlancK. (2011). The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood, 117:4826–4835.
28.
HsuWT, LinCH, ChiangBL, JuiHY, WuKK and LeeCM. (2013). Prostaglandin E2 potentiates mesenchymal stem cell-induced IL-10+IFN-γ+CD4+ regulatory T cells to control transplant arteriosclerosis. J Immunol, 190:2372–2380.
29.
DominiciM, Le BlancK, MuellerI, Slaper-CortenbachI, MariniF, KrauseD, DeansR, KeatingA, ProckopDj and HorwitzE. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8:315–317.
30.
WangM, YangY, YangD, LuoF, LiangW, GuoS and XuJ. (2009). The immunomodulatory activity of human umbilical cord blood-derived mesenchymal stem cells in vitro. Immunology, 126:220–232.
31.
LiCD, ZhangWY, LiHL, JiangXX, ZhangY, TangPH and MaoN. (2005). Mesenchymal stem cells derived from human placenta suppress allogeneic umbilical cord blood lymphocyte proliferation. Cell Res, 15:539–547.
32.
WangM, WindgassenD and PapoutsakisET. (2008). Comparative analysis of transcriptional profiling of CD3+, CD4+ and CD8+ T cells identifies novel immune response players in T-cell activation. BMC Genomics, 9:225
33.
WingK, YamaguchiT and SakaguchiS. (2011). Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation. Trends Immunol, 32:428–433.
34.
JagoCB, YatesJ, CâmaraNO, LechlerRI and LombardiG. (2004). Differential expression of CTLA-4 among T cell subsets. Clin Exp Immunol, 136:463–471.
35.
ChangCJ, YenML, ChenYC, ChienC, HuangHI, BaiCH and YenBL. (2006). Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-gamma. Stem Cells, 24:2466–2477.
36.
KalinskiP. (2012). Regulation of immune responses by prostaglandin E2. J Immunol, 188:21–28.
37.
FengG, GaoW, StromTB, OukkaM, FrancisRS, WoodKJ and BushellA. (2008). Exogenous IFN-gamma ex vivo shapes the alloreactive T-cell repertoire by inhibition of Th17 responses and generation of functional Foxp3+ regulatory T cells. Eur J Immunol, 38:2512–2527.
38.
WingK and SakaguchiS. (2010). Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol, 11:7–13.
39.
DuffnerUA, MaedaY, CookeKR, ReddyP, OrdemannR, LiuC, FerraraJL and TeshimaT. (2004). Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol, 172:7393–7398.
40.
KernS, EichlerH, StoeveJ, KlüterH and BiebackK. (2006). Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells, 24:1294–1301.
41.
WagnerW, RoderburgC, WeinF, DiehlmannA, FrankhauserM, SchubertR, EcksteinV and HoAD. (2007). Molecular and secretory profiles of human mesenchymal stromal cells and their abilities to maintain primitive hematopoietic progenitors. Stem Cells, 25:2638–2647.
42.
MuragliaA, CanceddaR and QuartoR. (2000). Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. J Cell Sci, 113:1161–1166.
43.
ManochantrS, U-pratyaY, KheolamaiP, RojphisanS, ChayosumritM, TantrawatpanC, SupokawejA and IssaragrisilS. (2013). Immunosuppressive properties of mesenchymal stromal cells derived from amnion, placenta, Wharton's jelly and umbilical cord. Intern Med J, 43:430–439.
44.
CutlerAJ, LimbaniV, GirdlestoneJ and NavarreteCV. (2010). Umbilical cord-derived mesenchymal stromal cells modulate monocyte function to suppress T cell proliferation. J Immunol, 185:6617–6623.
45.
LuanX, LiG, WangG, WangF and LinY. (2013). Human placenta-derived mesenchymal stem cells suppress T cell proliferation and support the culture expansion of cord blood CD34+ cells: a comparison with human bone marrow-derived mesenchymal stem cells. Tissue Cell, 45:32–38.
46.
LiCD, ZhangWY, LiHL, JiangXX, ZhangY, TangPH and MaoN. (2005). Mesenchymal stem cells derived from human placenta suppress allogeneic umbilical cord blood lymphocyte proliferation. Cell Res, 15:539–547.
47.
TipnisS, ViswanathanC and MajumdarAS. (2010). Immunosuppressive properties of human umbilical cord-derived mesenchymal stem cells: role of B7-H1 and IDO. Immunol Cell Biol, 88:795–806.
48.
RenG, ZhaoX, ZhangL, ZhangJ, L'HuillierA, LingW, RobertsAI, LeAD, ShiS, ShaoC and ShiY. (2010). Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol, 184:2321–2328.
49.
DamleNK, KlussmanK, LeytzeG, MyrdalS, AruffoA, LedbetterJA and LinsleyPS. (1994). Costimulation of T lymphocytes with integrin ligands intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 induces functional expression of CTLA-4, a second receptor for B7. J Immunol, 152:2686–2697.
50.
AvanziniMA, BernardoME, CometaAM, PerottiC, ZaffaroniN, NovaraF, VisaiL, MorettaA, Del FanteC, et al. (2009). Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood- and bone marrow-derived progenitors. Haematologica, 94:1649–1660.
51.
PrasannaSJ, GopalakrishnanD, ShankarandSR and VasandanAB. (2010). Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS One, 5:e9016
52.
LuY and WallerEK. (2009). Dichotomous role of interferon-gamma in allogeneic bone marrow transplant. Biol Blood Marrow Transplant, 15:1347–1353.
53.
PolchertD, SobinskyJ, DouglasG, KiddM, MoadsiriA, ReinaE, GenrichK, MehrotraS, SettyS, SmithB and BartholomewA. (2008). IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol, 38:1745–1755.
54.
DeuseT, StubbendorffM, Tang-QuanK, PhillipsN, KayMA, EiermannT, PhanTT, VolkHD, ReichenspurnerH, RobbinsRC and SchrepferS. (2011). Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells. Cell Transplant, 20:655–667.
55.
MourezR, FrançoisM, BoivinMN, StaggJ and GalipeauJ. (2007). Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density. J Immunol, 179:1549–1558.
56.
JonesBJ, BrookeG, AtkinsonK and McTaggartSJ. (2007). Immunosuppression by placental indoleamine 2,3-dioxygenase: a role for mesenchymal stem cells. Placenta, 28:1174–1181.
57.
BoassoA, HerbeuvalJP, HardyAW, WinklerC and ShearerGM. (2005). Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells. Blood, 105:1574–1581.
58.
YooKH, JangIK, LeeMW, KimHE, YangMS, EomY, LeeJE, KimYJ, YangSK, et al. (2009). Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. Cell Immunol, 259:150–156.
59.
ChiesaS, MorbelliS, MorandoS, MassolloM, MariniC, BertoniA, FrassoniF, BartoloméST, SambucetiG, TraggiaiE and UccelliA. (2011). Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. Proc Natl Acad Sci U S A, 108:17384–17389.
60.
KnissDA, ZimmermanPD, FertelRH and IamsJD. (1993). Transforming growth factor-beta potentiates epidermal growth factor-induced prostaglandin E2 production in amnion cells. Prostaglandins, 45:27–33.
61.
ChenK, WangD, DuWT, HanZB, RenH, ChiY, YangSG, ZhuD, BayardandF and HanZC. (2010). Human umbilical cord mesenchymal stem cells hUC-MSCs exert immunosuppressive activities through a PGE2-dependent mechanism. Clin Immunol, 135:448–458.
62.
JuiHY, LinCH, HsuWT, LiuYR, HsuRB, ChiangBL, TsengWY, ChenMF, WuKK and LeeCM. (2012). Autologous mesenchymal stem cells prevent transplant arteriosclerosis by enhancing local expression of interleukin-10, interferon-γ, and indoleamine 2,3-dioxygenase. Cell Transplant, 21:971–984.
63.
WagnerW, BorkS, HornP, KrunicD, WalendaT, DiehlmannA, BenesV, BlakeJ, HuberFX, et al. (2009). Aging and replicative senescence have related effects on human stem and progenitor cells. PLoS One, 4:e5846
64.
RaggiC and BerardiAC. (2012). Mesenchymal stem cells, aging and regenerative medicine. Muscles Ligaments Tendons J, 2:239–242.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
